drugset / Trial / NCT00423748

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

NCT00423748

Phase 3 Completed 186 enrolled Gilead Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.

Timeline

Start
2003-12
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambrisentan Small molecule